spinal orthoses

PreclinicalBiologic

IIstanbul Medipol University Hospital

spinal orthoses is one of 13 biologic programs targeting Scoliosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScoliosisActive, not recruiting

ScoliosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Scoliosis

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

3 2

Cyklokapron

JJ Molner

Approved

2 3

Marcaine

IInnocoll

Approved

1 4

Spravato

WWim Janssens

Approved

1 5

Cleviprex

Chiesi Farmaceutici S.p.A.

Catapres

Tegileridine

1 8

Ferric Carboxymaltose IV

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 9

Anerem

AAcacia Pharma Ltd

Preclinical

1 10

Plasmalyte

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Scoliosis1 trial

Effect Spinal Orthosis on Sagittal and Frontal Parameters in Scoliosis

Completed·IIstanbul Medipol University Hospital·N/A·NCT06569030·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for spinal orthoses. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — spinal orthoses compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for spinal orthoses. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istanbul Medipol University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IIstanbul Medipol University Hospital

spinal orthoses

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Scoliosis1 trial

References

Drug Info

Quick Facts

Related News